MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

After hours: February 14 at 5:37:46 PM EST Loading Chart for FORM ...

Objectives The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of waveLINE-010, a pivotal ...

Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk. In the cohort the ...

Supported by AstraZeneca. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank Marco Cicero, Ph.D., and Cindy Gobbel, Ph.D., of Peloton ...

Metronomic chemotherapy (MC) is emerging as a groundbreaking treatment for pediatric neuroblastoma, offering a more accessible and manageable option for children with high-risk and relapsed/refractory ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

18 Seven of the 10 patients had already experienced episodes of nephritis requiring steroids plus cyclophosphamide ... of therapy with certain recombinant forms of erythropoietin (EPO), probably ...